Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab

China’s NMPA Gives Go-Ahead For Phase I Trial On Stelara Biosimilar

Executive Summary

China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.

You may also be interested in...



Meiji And Dong-A Start European Ustekinumab Trial

A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.

Bio-Thera Solutions Has China’s First Adalimumab Biosimilar

Bio-Thera Solutions has secured only the second biosimilar approval ever from China’s NMPA, and the country’s first biosimilar approval for a rival to Humira (adalimumab).

Formycon Begins Biosimilar Ustekinumab Trial

Formycon has become the latest firm to announce a Phase I trial for a proposed biosimilar ustekinumab rival to Janssen’s Stelara, following hot on the heels of NeuClone.

Related Content

Topics

UsernamePublicRestriction

Register

GB149444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel